



## Neurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares

February 20, 2015

SAN DIEGO, Feb. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,041,600 shares of Neurocrine's common stock at the public offering price of \$36.00 per share, less underwriting discounts and commissions. As a result, the total number of shares being sold in the public offering is 7,985,600 shares. The closing of the sale of all the shares in the offering is expected to occur on or about February 24, 2015, subject to customary closing conditions.

J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for this offering, Jefferies LLC and Barclays Capital Inc. are acting as co-lead managers for this offering and Cowen and Company, LLC and Nomura Securities International, Inc. are acting as co-managers for this offering. The securities described above are being offered by Neurocrine pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC") on February 25, 2014, which became automatically effective by rule of the SEC upon filing. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at [www.sec.gov](http://www.sec.gov). The offering is being conducted only by means of the prospectus supplement and accompanying prospectus, copies of which may be obtained (when available) from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 866-803-9204, or from Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, or by phone at 1-800-503-4611, or by email at [prospectus.CPDG@db.com](mailto:prospectus.CPDG@db.com).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

### About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. Neurocrine's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor and evolve into a fully-integrated pharmaceutical company.

*In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties such as those, among others, relating to Neurocrine's expectations regarding the completion of its public offering. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with Neurocrine's business and finances in general, and the other risks described in Neurocrine's annual report on Form 10-K for the year ended December 31, 2014. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.*

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-inc-announces-exercise-in-full-of-underwriters-option-to-purchase-additional-shares-300038948.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Investor Relations, +1-858-617-7600